PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023 RESULTS AND PROVIDES AN UPDATE ON THE OPERATIONAL REORGANIZATION AND RECAPITALIZATION Company will host a conference call with live webcast presentation today at 14:30 CEST / 13:30 BST (UK) / 08:30 EDT (US) to discuss H1 2023 results Solid performance with 22% growth of oncology cartridge revenue, a 40% gross margin on product sales and a 20% improvement in EBITDA to EUR -14.5mOper
PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023 RESULTS AND PROVIDES AN UPDATE ON THE OPERATIONAL REORGANIZATION AND.
Due to rising demand for personalized medicine, effective drug discovery, and an increase in the prevalence of chronic diseases, the global organoids and
P. All stages of P. vivax accumulated in the spleen at magnitudes unexplainable by replication occurring in the circulation alone, with the proportion of each stage in the spleen consistent with the duration in their lifecycle. What do these findings mean? Taking advantage of the large physiological splenic reservoir of immature reticulocytes, the majority of the P. vivax lifecycle can take place in the spleen in chronic malaria. Chronic vivax malaria should be considered predominantly an infection of the reticulocyte-rich spleen, with secondary involvement of the intravascular compartment. The spleen is not solely a compartment for parasite destruction and clearance.